牛牛AI助理已提取核心訊息
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC, disclosing a 9.99% ownership stake in Vivos Therapeutics, Inc., amounting to 175,099 shares. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to beneficially own the securities held by the Master Fund. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Vivos Therapeutics. The filing was signed and dated February 14, 2024, by Steven Boyd, Managing Member of Armistice Capital, LLC.
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC, disclosing a 9.99% ownership stake in Vivos Therapeutics, Inc., amounting to 175,099 shares. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to beneficially own the securities held by the Master Fund. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Vivos Therapeutics. The filing was signed and dated February 14, 2024, by Steven Boyd, Managing Member of Armistice Capital, LLC.
2023年12月31日，Armistice Capital, LLC和Steven Boyd向美國證券交易委員會提交了附表13G，披露了Vivos Therapeutics, Inc. 9.99％的所有權，共計175,099股。作爲停戰資本主基金有限公司的投資經理，停戰資本對主基金持有的證券行使投票權和投資權。史蒂芬·博伊德作爲停戰資本的管理成員，也可能被視爲實益擁有主基金持有的證券。文件顯示，這些股份是在正常業務過程中收購的，不是爲了改變或影響Vivos Therapeutics的控制權。該文件由停戰資本有限責任公司管理成員史蒂芬·博伊德於2024年2月14日簽署並註明日期。
2023年12月31日，Armistice Capital, LLC和Steven Boyd向美國證券交易委員會提交了附表13G，披露了Vivos Therapeutics, Inc. 9.99％的所有權，共計175,099股。作爲停戰資本主基金有限公司的投資經理，停戰資本對主基金持有的證券行使投票權和投資權。史蒂芬·博伊德作爲停戰資本的管理成員，也可能被視爲實益擁有主基金持有的證券。文件顯示，這些股份是在正常業務過程中收購的，不是爲了改變或影響Vivos Therapeutics的控制權。該文件由停戰資本有限責任公司管理成員史蒂芬·博伊德於2024年2月14日簽署並註明日期。
有用
沒用
